Review highlights the advantages of PET/MRI for treatment response assessment in rectal cancer, suggesting improved diagnostic capabilities.
Imaging plays a critical role in the assessment of patients with rectal cancer, and positron emission tomography/magnetic resonance imaging (PET/MRI) has shown superiority in specific clinical scenarios. This review describes the potential contribution of ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) PET/MRI relative to standard of care imaging-computed tomography (CT), MRI, or PET/CT-in the evaluation of patients with rectal cancer in settings such as primary staging, treatment response assessment, and recurrence detection. We discuss ¹⁸F-FDG PET/MRI protocols and clinical workflow, as well as highlighting the potential clinical superiority of PET/MRI over other imaging modalities.
No takes yet. Share an insight, caveat, or question.
Zampieri et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: